TY - CHAP
T1 - Cognition in Parkinson's disease
AU - O'Callaghan, Claire
AU - Lewis, Simon J. G.
PY - 2017
Y1 - 2017
N2 - Cognitive decline is now recognized as a common nonmotor symptom of Parkinson's disease, and it has been the subject of increasing research in recent decades. Cognitive deficits in Parkinson's disease can be distinguished as dopaminergically mediated executive dysfunction seen in the milder stages vs a global dementia syndrome that can occur with disease progression. The neural basis of these deficits has been explored from the perspective of multimodal imaging techniques to measure the structural, functional, and metabolic correlates of cognitive decline in Parkinson's disease. Increasingly, changes in neurotransmitter systems beyond dopamine, including the noradrenergic, serotonergic, and cholinergic systems, are being recognized for their contribution to cognitive decline. The impact of certain genetic variations on cognitive function has also been established, including links between cognitive decline and polymorphisms affecting COMT, MAPT, APOE, and GBA genotypes. Although therapeutic options for cognitive decline are still far less established than for motor systems, both pharmacological and nonpharmacological strategies are continuing to develop.
AB - Cognitive decline is now recognized as a common nonmotor symptom of Parkinson's disease, and it has been the subject of increasing research in recent decades. Cognitive deficits in Parkinson's disease can be distinguished as dopaminergically mediated executive dysfunction seen in the milder stages vs a global dementia syndrome that can occur with disease progression. The neural basis of these deficits has been explored from the perspective of multimodal imaging techniques to measure the structural, functional, and metabolic correlates of cognitive decline in Parkinson's disease. Increasingly, changes in neurotransmitter systems beyond dopamine, including the noradrenergic, serotonergic, and cholinergic systems, are being recognized for their contribution to cognitive decline. The impact of certain genetic variations on cognitive function has also been established, including links between cognitive decline and polymorphisms affecting COMT, MAPT, APOE, and GBA genotypes. Although therapeutic options for cognitive decline are still far less established than for motor systems, both pharmacological and nonpharmacological strategies are continuing to develop.
KW - Acetylcholine
KW - Dopamine
KW - Genetic impact on cognition
KW - Neurotransmitters and cognition
KW - Noradrenaline
KW - Parkinson's disease cognition
KW - Parkinson's disease dementia
KW - Parkinson's disease mild cognitive impairment
KW - Serotonin
UR - http://www.scopus.com/inward/record.url?scp=85020815882&partnerID=8YFLogxK
U2 - 10.1016/bs.irn.2017.05.002
DO - 10.1016/bs.irn.2017.05.002
M3 - Chapter
C2 - 28802933
AN - SCOPUS:85020815882
T3 - International Review of Neurobiology
SP - 557
EP - 583
BT - Nonmotor Parkinson's
A2 - Chaudhuri, K. Ray
A2 - Titova, Nataliya
PB - Elsevier Academic Press
CY - Cambridge
ER -